Skip to main content

From the Helm: Clarity Pharmaceuticals Executive Chairman, Alan Taylor

Bell Direct
May 24, 2024

Embark on a journey of discovery with Dr. Alan as he unveils the cutting-edge breakthroughs of Clarity Pharma, a pioneering force in the relentless fight against cancer through next-generation radiopharmaceuticals. In this instalment of our From the helm series, Bell Direct’s Grady Wulff speaks to Clarity Pharmaceuticals (ASX:CU6) Executive Chairman, Dr Alan Taylor.

Clarity Pharmaceuticals specialises in the development of Targeted Copper Theragnostic for the imaging and treatment of selected cancers. Clarity Pharma has an extensive program of clinical development for imaging and cancer therapy with a series of important data readouts over the next few years.

In this video Dr. Alan discusses:

  • (1:27) an overview of the company, including their 7 clinical trials
  • (3:35) the promising results from their SECuRE trial
  • (11:55) why the radiopharmaceutical market is booming
  • (14:47) why Clarity Pharma could be an investment opportunity.

Livewire Markets & Bell Direct partnership

Arnie Selvarajah
September 20, 2019

Platinum Global Fund

Bell Direct
August 23, 2019

Bell Global Emerging Companies Fund

Bell Direct
August 23, 2019

June Market Overview

Julia Lee
July 11, 2019

May Market Overview

Julia Lee
May 31, 2019

April Market Overview

Julia Lee
April 29, 2019

Investing in ETFs

Bell Direct
April 17, 2019

March Market Overview

Julia Lee
March 28, 2019

Investing in Alternatives

Julia Lee
March 1, 2019